The resulting increased systemic cytokine production contributes to the pathophysiology of severe COVID-19, including hypotension, ARDS, which might be treated with IL-6 antagonists, i.e., tocilizumab, sarilumab, and siltuximab. Here, IL6 is linked to COVID-19.